14.02.2013
- Swiss group Actelion has raised its dividend 25% as it awaits a U.S. regulatory decision on a new heart and lung drug it hopes will cut its dependency on current mainstay Tracleer...
19.07.2012
- Actelion raised its earnings outlook for 2012 on Thursday as cost cuts helped Europe's biggest biotech company to post a first-half profit despite its most important drug facing...
25.05.2012
- Knock-out data for Actelion's big new drug hope could be a double-edged sword for embattled founder and CEO Jean-Paul Clozel, making it a worthy buy for pharma companies hungry for...
19.04.2012
- Europe's largest biotech company Actelion said it expects results of a key late-stage trial on heart and lung disease drug macitentan in the next few weeks after a strong Swiss...
